[Ip-health] Norwegian parliament turns down proposal to issue Spinraza compulsory license
jens at plahte.info
Wed May 30 00:54:46 PDT 2018
On Thursday last week a majority vote in the Norwegian parliament
Stortinget turned down a proposal to request that the Government issue a
compulsory license for the drug Spinraza (nusinersen), which is used to
treat the serious congenital condition Spinal muscular atrophy (SMA).
Recently, Norwegian health authorities concluded drawn-out negotiations
with Spinraza manufacturer Biogen to purchase the drug for use in less
than 18 year old patients, but not in adults, at a non-disclosed price.
Biogen's initial offer was NOK 1 million per dose (USD 121 000), or NOK
7 million per patient for the initial year of treatment.
The bill, which was submitted by representatives of the Socialist Party
and supported by the Christian Democratic Party, made reference to the
TRIPS regulations, and proposed that Norway should seek ways to
establish national manufacturing capacities, or alternatively to
parallel import the drug. The bill also mentioned that US authorities
had succeeded in lowering the price of Bayer's antibiotic ciprofloaxacin
by threatening to compulsory licence the drug as a defense against the
anthrax attacs in 2001.
During the debate the bill received strong opposition and criticism from
the Conservative Party representative, and his fellow party member the
Minster og Health Mr. Bent Høie pointed out that 1) the current
situation represents no public health emergency that could justify
issuance of a compulsory license, 2) there is no production facility
available that could manufacture nusinersen, and 3) due to the data
exclusivity regulations new clinical trails would have to be conducted.
The Labor Party added weight to the Government coalition's votes to
reject the bill.
Plahte Research & Consulting
Mob.: +47 915 888 56
More information about the Ip-health